Oncotelic Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Oncotelic Therapeutics, Inc. (OTLC) filed its annual report for the fiscal year ended December 31, 2025, highlighting a significant increase in the fair value of its investment in its joint venture, GMP Biotechnology Limited (GMP Bio).
OQB
Oncotelic Therapeutics' 2024 annual report details ongoing efforts to develop cancer treatments, manage financial constraints, and advance strategic partnerships, particularly through its joint venture GMP Biotechnology.
OQB
Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, announced its financial results for the year ended December 31, 2023, highlighting progress in its joint venture and ongoing development programs.